Anxiety Disorder and Depression Treatment Market Demand and Forecasts to 2026

1
Anxiety Disorder and Depression Treatment Market
To Reach USD 18.90 Billion By 2026
www.reportsanddata.com
sales_at_reportsanddata.com
2
Market Summary
The rise in the graying population and minimal
side effects associated with the treatment are
some of the factors boosting the market for
Anxiety Disorder and Depression
Treatment. Market Size USD 15.60 Billion in
2018, Market Growth - CAGR of 2.4, Market Trends
Increase in awareness regarding mental health.
3
Our Approach
Market Summary

• The Global Anxiety Disorder and Depression
  Treatment Market is forecast to reach USD18.90
  Billion by 2026, according to a new report by
  Reports and Data. There has been a continued rise
  in the rate of depression and anxiety in the
  global healthcare scenario. Such a rise in the
  incidence rate of depression and anxiety has
  resulted in focusing on the global healthcare
  scenario and reduce the incidence rate of such
  mental healthcare condition. In the year 2018,
  more than 300 million individuals of all ages
  were suffering from depression in the global
  scenario. There have been 800,000 incidents of
  suicides in the same year, the reason behind
  which has been primarily, depression and anxiety
  disorders. Such a rise in the incidence of rate
  of depression and anxiety are one of the major
  factors driving the global Anxiety Disorder and
  Depression Treatment Market.
• Globally, incidences of depression and mental
  health are continuously increasing in the elderly
  population. This population is prone to mental
  health issues like dementia, phobia and anxiety
  disorders. Hence, the increase in the graying
  population is also contributing to the rising
  demand for antidepressants and therapies to treat
  the mental health condition during the forecast
  period. In the year 2018, the global Anxiety
  Disorder and Depression Treatment Market was
  dominated by North America. This region can be
  forecasted to continue this domination throughout
  the forecast period.
• Key participants include Johnson Johnson, Inc.,
  Pfizer, GlaxoSmithKline plc., Lundbeck A/S, Inc.,
  Sanofi- Aventis, Merck Company, AstraZeneca
  PLC., Forest Laboratories, Eli Lilly and Company,
  Bristol-Myers Squibb Company among others
• To Get Sample Copy of Report visit
  https//www.reportsanddata.com/sample-enquiry-form
  /1405

4
Our Approach
Market Summary

• Drug class Outlook (Revenue, USD Billion
  2016-2026)
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Antidepressant Drugs
• Tricyclic Antidepressants (TCAs)
• Serotonin-Norepinephrine Reuptake Inhibitors
  (SNRIs)
• Monoamine Oxidase Inhibitors (MAOIs)
• Benzodiazepines
• Atypical Antipsychotics
• Anticonvulsants
• Beta-Blockers
• Others
• Therapies Outlook (Revenue, USD Billion
  2016-2026)
• Electroconvulsive Therapy (ECT)
• Cognitive Behavior Therapy (CBT)
• Psychotherapy
• Deep Brain Stimulation
• Transcranial Magnetic Stimulation (TMS)
• Cranial electrotherapy stimulation (CES)

5
Our Approach
Market Summary

• Devices Outlook (Revenue, USD Billion 2016-2026)
• Cranial electrotherapy stimulator
• Fisher-Wallace stimulator market
• Application Outlook (Revenue, USD Billion
  2016-2026)
• Phobia
• Major Depressive Disorder
• Obsessive Compulsive Disorder (OCD)
• Post-traumatic stress disorder
• Others
• End-users Outlook (Revenue, USD Billion
  2016-2026)
• Hospitals
• Mental healthcare centers
• NGOs
• Asylums
• Click here to Get customization check available
  discount for the report _at_ https//www.reportsandda
  ta.com/discount-enquiry-form/1405

6
Our Approach
Market Summary

• Further key findings from the report suggest
• The rising rate of occurrence of depression and
  anxiety is one of the contributing factors for
  the high consumption rate of anti-depressants.
• This rise in the occurrence rate of anxiety and
  depression is one of the major driving factors
  for global Anxiety Disorder and Depression
  Treatment Market, contributing to market growth.
• In the segment Drug class, the highest market
  share was held by antidepressants, in the year
  2018, followed by antidepressants.
  Serotonin-Norepinephrine Reuptake Inhibitors
  (SNRIs) dominated the markets in the year 2018,
  with a market share of 28.
• Rise in the occurrence rate of anxiety and
  depression along with incidents of suicide, the
  edifice of which were anxiety disorders have also
  made a positive impact on the global Anxiety
  Disorder and Depression Treatment M
• As a result of such incidents of suicide, there
  has been a rise in demand for therapies. In the
  year 2018, Cognitive Behavior Therapy CBT
  dominated the market with a market share of 30.
• During the forecast period, CBT is forecasted to
  hold a market share of 31 by 2026.
• Browse the comprehensive TOC and data tables _at_
  https//www.reportsanddata.com/report-detail/anxie
  ty-disorder-and-depression-treatment-market

7
Our Approach
About Us

• Reports and Data is a market research and
  consulting company that provides syndicated
  research reports, customized research reports,
  and consulting services. Our solutions purely
  focus on your purpose to locate, target and
  analyze consumer behavior shifts across
  demographics, across industries and help clients
  make a smarter business decision. We offer market
  intelligence studies ensuring relevant and
  fact-based research across a multiple industries
  including Healthcare, Technology, Chemicals,
  Power, and Energy. We consistently update our
  research offerings to ensure our clients are
  aware about the latest trends existent in the
  market. Reports and Data has a strong base of
  experienced analysts from varied areas of
  expertise.
• Contact Us
• John Watson
• Head of Business Development
• Reports And Data Web www.reportsanddata.com
• Direct Line 1-212-710-1370
• E-mail sales_at_reportsanddata.com